Details
Stereochemistry | ACHIRAL |
Molecular Formula | C26H28N3 |
Molecular Weight | 382.5206 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 1 |
Charge | 1 |
SHOW SMILES / InChI
SMILES
CN(C)C1=CC2=C(C=C1)[N+](C)=C(\C=C\C3=C(C)N(C(C)=C3)C4=CC=CC=C4)C=C2
InChI
InChIKey=QMHSXPLYMTVAMK-UHFFFAOYSA-N
InChI=1S/C26H28N3/c1-19-17-21(20(2)29(19)24-9-7-6-8-10-24)11-13-23-14-12-22-18-25(27(3)4)15-16-26(22)28(23)5/h6-18H,1-5H3/q+1
Pyrvinium (Viprynium) is an anthelmintic effective for pinworms. Pyrvinium is used in the treatment of enterobiasis caused by Enterobius vermicularis (pinworm). Pyrvinium has being shown to be a potent inhibitor of Wnt signaling (EC(50) of ∼10 nM). Pyrvinium binds all casein kinase 1 (CK1) family members in vitro at low nanomolar concentrations and pyrvinium selectively potentiates casein kinase 1α (CK1α) kinase activity. Pyrvinium pamoate (PP) is a potent noncompetitive inhibitor of the androgen receptor (AR). A noncompetitive AR inhibitor pyrvinium has significant potential to treat CRPC, including cancers driven by ligand-independent AR signaling.
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL2793 |
|||
Target ID: CHEMBL612855 Sources: https://www.ncbi.nlm.nih.gov/pubmed/18591280 |
354.0 nM [IC50] | ||
Target ID: CHEMBL1871 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Curative | Unknown Approved UseUnknown |
|||
Primary | Unknown Approved UseUnknown |
|||
Curative | POVAN Approved UsePyrvinium is used to treat pinworms (enterobiasis). |
|||
Primary | Unknown Approved UseUnknown |
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/1269218
single 350-mg dose
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/25060218
Pyrvinium blocked colon cancer cell growth in vitro in a dose-dependent manner with great differences in the inhibitory concentration (IC(50)), ranging from 0.6 × 10(-6) to 65 × 10(-6) mol/L for colon cancer cells with mutations in WNT signaling.
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
FDA ORPHAN DRUG |
458314
Created by
admin on Fri Dec 15 16:20:37 GMT 2023 , Edited by admin on Fri Dec 15 16:20:37 GMT 2023
|
||
|
NCI_THESAURUS |
C276
Created by
admin on Fri Dec 15 16:20:37 GMT 2023 , Edited by admin on Fri Dec 15 16:20:37 GMT 2023
|
||
|
WHO-ATC |
P02CX01
Created by
admin on Fri Dec 15 16:20:37 GMT 2023 , Edited by admin on Fri Dec 15 16:20:37 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
100000092353
Created by
admin on Fri Dec 15 16:20:37 GMT 2023 , Edited by admin on Fri Dec 15 16:20:37 GMT 2023
|
PRIMARY | |||
|
C77330
Created by
admin on Fri Dec 15 16:20:37 GMT 2023 , Edited by admin on Fri Dec 15 16:20:37 GMT 2023
|
PRIMARY | |||
|
SUB04153MIG
Created by
admin on Fri Dec 15 16:20:37 GMT 2023 , Edited by admin on Fri Dec 15 16:20:37 GMT 2023
|
PRIMARY | |||
|
DTXSID2043795
Created by
admin on Fri Dec 15 16:20:37 GMT 2023 , Edited by admin on Fri Dec 15 16:20:37 GMT 2023
|
PRIMARY | |||
|
3178
Created by
admin on Fri Dec 15 16:20:37 GMT 2023 , Edited by admin on Fri Dec 15 16:20:37 GMT 2023
|
PRIMARY | |||
|
C024631
Created by
admin on Fri Dec 15 16:20:37 GMT 2023 , Edited by admin on Fri Dec 15 16:20:37 GMT 2023
|
PRIMARY | |||
|
22526
Created by
admin on Fri Dec 15 16:20:37 GMT 2023 , Edited by admin on Fri Dec 15 16:20:37 GMT 2023
|
PRIMARY | |||
|
6B9991FLU3
Created by
admin on Fri Dec 15 16:20:37 GMT 2023 , Edited by admin on Fri Dec 15 16:20:37 GMT 2023
|
PRIMARY | |||
|
Pyrvinium
Created by
admin on Fri Dec 15 16:20:37 GMT 2023 , Edited by admin on Fri Dec 15 16:20:37 GMT 2023
|
PRIMARY | |||
|
7187-62-4
Created by
admin on Fri Dec 15 16:20:37 GMT 2023 , Edited by admin on Fri Dec 15 16:20:37 GMT 2023
|
PRIMARY | |||
|
2335
Created by
admin on Fri Dec 15 16:20:37 GMT 2023 , Edited by admin on Fri Dec 15 16:20:37 GMT 2023
|
PRIMARY | |||
|
DB06816
Created by
admin on Fri Dec 15 16:20:37 GMT 2023 , Edited by admin on Fri Dec 15 16:20:37 GMT 2023
|
PRIMARY | |||
|
35163
Created by
admin on Fri Dec 15 16:20:37 GMT 2023 , Edited by admin on Fri Dec 15 16:20:37 GMT 2023
|
PRIMARY | RxNorm |
ACTIVE MOIETY
SALT/SOLVATE (PARENT)
SALT/SOLVATE (PARENT)
SALT/SOLVATE (PARENT)